BMO Capital analyst David Lebowitz reiterated an Outperform rating and $319.00 price target on Ascendis Pharma (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE